N@N

GTXI, PSB, PZA, DEPO, DMRC, ALNY Are Seasonally Ripe To Go Up In the Next Five Weeks

^{Published on 2016-11-21 01:46:03 - WOPRAI}
 

November 21, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of GTx Inc. (NASDAQ:GTXI), PS Business Parks Inc. (NYSE:PSB), PowerShares Insured National Municipal Bond Portfolio (NYSE:PZA), Depomed Inc. (NASDAQ:DEPO), Digimarc Corporation (NASDAQ:DMRC), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

The following stocks are expected to go Up:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  GTXI    GTx Inc.                         17.68%           75.00% (9 of 12)     Tuesday, January 3rd 2017
  PSB     PS Business Parks Inc.           5.18%            77.78% (14 of 18)    Friday, December 23rd 2016
  PZA     PowerShares Insured National Municipal Bond Portfolio  0.14%            88.89% (8 of 9)      Tuesday, November 22nd 2016
  DEPO    Depomed Inc.                     12.18%           88.89% (16 of 18)    Wednesday, December 28th 2016
  DMRC    Digimarc Corporation             11.40%           87.50% (7 of 8)      Tuesday, December 20th 2016
  ALNY    Alnylam Pharmaceuticals, Inc.    16.05%           91.67% (11 of 12)    Tuesday, January 3rd 2017

PS Business Parks Inc. (NYSE:PSB) - PS Business Parks, Inc., a real estate investment trust (REIT), together with its subsidiaries, engages in the acquisition, development, ownership, and operation of commercial properties primarily multi-tenant flex, office, and industrial space. As of December 31, 2007, the company owned and operated approximately 19.6 million rentable square feet of commercial space located in Arizona, California, Florida, Maryland, Oregon, Texas, Virginia, and Washington, as well as managed approximately 1.4 million rentable square feet. It also owned approximately 6.4 acres of land in Northern Virginia; 14.9 acres in Portland, Oregon; and 10.0 acres in Dallas, Texas for the development of commercial properties. PS Business Parks has elected to be taxed as a REIT under the Internal Revenue Code and would not be subject to federal income tax to the extent it distributes at least 90% of its REIT taxable income to its shareholders. The company was founded in 1983. It was formerly known as Public Storage Properties XI, Inc. and changed its name to PS Business Parks, Inc. in 1998. The company is based in Glendale, California..

PowerShares Insured National Municipal Bond Portfolio (NYSE:PZA) - Provena Foods Inc.

Depomed Inc. (NASDAQ:DEPO) - Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology; and Cebranopadol, a molecule for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California..

Digimarc Corporation (NASDAQ:DMRC) - Digimarc Corporation provides media identification and management solutions to commercial entities and government customers in the United States and internationally. It develops intellectual property to differentiate products and technology, mitigate infringement risks, and develop opportunities for licensing; and offers patents portfolio covering a range of methods, applications, system architectures, and business processes. The company s patents are related to various methods for embedding and decoding digital information in video, audio, and images, whether the content is rendered in analog or digital formats. Its solutions are used to identify, track, manage, and protect content; and to enable new consumer applications to access networks and information from personal computers and mobile devices. The company s patented inventions are used in various media identification and management products and solutions supporting various media objects, such as movies, music, banknotes, secure credentials, and consumer packaged goods. It primarily offers Digimarc Discover and Digimarc Barcode intuitive computing platform that are designed to optimize the identification of various consumer brand impressions facilitating mobile-centric shopping. The company provides its solutions directly and through its business partners. Digimarc Corporation is headquartered in Beaverton, Oregon..

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias. Its product development programs also include ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia; ALN-HBV for the treatment of Hepatitis B virus; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Ionis Pharmaceuticals, Inc.; Novartis Pharma AG; Novartis/Arrowhead; F. Hoffmann-La Roche Ltd; Roche/Arrowhead; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Ascletis BioScience Co., Ltd.; Monsanto Company; Sanofi Genzyme; The Medicines Company; Arbutus Biopharma Corporation; Protiva Biotherapeutics, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net